ABN AMRO Bank N.V. Decreases Stock Position in Stryker Corporation $SYK

Key Points

• ABN AMRO halved its Stryker position in the second quarter, selling 274,778 shares and retaining 274,441 shares worth about $86.4 million. Institutional investors and hedge funds collectively own 77.09% of SYK.
• Wall Street remains broadly bullish: analysts give Stryker a “Moderate Buy” consensus rating, with an average price target of $386.28 versus the reported share price of $338.80.
• Stryker reported stronger-than-expected quarterly results, including $3.69 in adjusted EPS and $6.59 billion in revenue, while revenue rose 9.4% year over year. The company also declared a quarterly dividend of $0.88, implying a 1.0% annual yield.

ABN AMRO Bank N.V. trimmed its position in shares of Stryker Corporation (NYSE:SYK - Free Report) by 50.0% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 274,441 shares of the medical technology company's stock after selling 274,778 shares during the quarter. Stryker makes up approximately 1.1% of ABN AMRO Bank N.V.'s investment portfolio, making the stock its 29th largest position. ABN AMRO Bank N.V. owned about 0.07% of Stryker worth $86,360,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the company. Varma Mutual Pension Insurance Co raised its holdings in shares of Stryker by 10.5% during the 4th quarter. Varma Mutual Pension Insurance Co now owns 53,610 shares of the medical technology company's stock worth $18,842,000 after acquiring an additional 5,100 shares during the period. QRG Capital Management Inc. boosted its position in shares of Stryker by 7.4% during the 4th quarter. QRG Capital Management Inc. now owns 60,548 shares of the medical technology company's stock valued at $21,281,000 after acquiring an additional 4,186 shares during the last quarter. Swedbank AB grew its holdings in shares of Stryker by 6.6% in the fourth quarter. Swedbank AB now owns 129,027 shares of the medical technology company's stock valued at $45,349,000 after purchasing an additional 7,934 shares during the period. Crossmark Global Holdings Inc. grew its holdings in shares of Stryker by 31.1% in the fourth quarter. Crossmark Global Holdings Inc. now owns 26,820 shares of the medical technology company's stock valued at $9,426,000 after purchasing an additional 6,367 shares during the period. Finally, Royal Bank of Canada increased its position in Stryker by 6.5% during the first quarter. Royal Bank of Canada now owns 3,273,232 shares of the medical technology company's stock worth $1,075,552,000 after purchasing an additional 199,863 shares during the last quarter. 77.09% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have weighed in on SYK. UBS Group assumed coverage on shares of Stryker in a report on Tuesday, July 28th. They issued a "buy" rating and a $400.00 target price on the stock. Robert W. Baird set a $385.00 price target on shares of Stryker in a report on Friday, May 1st. JPMorgan Chase & Co. reduced their price target on shares of Stryker from $400.00 to $350.00 and set an "overweight" rating on the stock in a research report on Friday, July 31st. Citigroup reiterated a "buy" rating on shares of Stryker in a report on Thursday. Finally, BMO Capital Markets began coverage on Stryker in a research report on Wednesday, July 8th. They issued an "outperform" rating and a $369.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $386.28.

Stryker Price Performance

Shares of SYK opened at $338.80 on Monday. Stryker Corporation has a 1-year low of $281.00 and a 1-year high of $396.86. The stock has a market cap of $129.95 billion, a PE ratio of 35.11, a P/E/G ratio of 2.16 and a beta of 0.76. The firm has a 50-day simple moving average of $324.61 and a two-hundred day simple moving average of $333.40. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping the consensus estimate of $3.49 by $0.20. The firm had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The business's revenue for the quarter was up 9.4% compared to the same quarter last year. During the same period in the prior year, the business posted $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, analysts forecast that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a $0.88 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.0%. Stryker's payout ratio is presently 36.48%.

Insiders Place Their Bets

In other news, Director Ronda E. Stryker sold 310,000 shares of Stryker stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the sale, the director directly owned 1,924,880 shares of the company's stock, valued at approximately $601,005,282.40. The trade was a 13.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, VP Robert S. Fletcher sold 4,544 shares of the business's stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the sale, the vice president owned 10,582 shares in the company, valued at $3,247,298.34. This represents a 30.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.60% of the stock is owned by corporate insiders.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source